Background {#Sec1}
==========

The severity of neurodegeneration in Alzheimer's disease (AD) correlates with the soluble amyloid beta (Aβ) level in the brain \[[@CR1]\]. Aβ binds selectively and with high affinity to neuronal α7 nicotinic acetylcholine receptors (α7nAChRs), leading to intraneuronal Aβ~42~ accumulation, tau phosphorylation, and cholinergic dysfunction \[[@CR2]--[@CR5]\]. Therefore, chronic perturbation of the α7nAChRs by Aβ may contribute to neuronal dysfunctions and neurodegeneration leading to the formation of Aβ-rich plaque and neurofibrillary pathologies, which may be reduced by treatments that disrupt the Aβ~42~-α7nAChR interaction. This hypothesis is supported by data showing that S 24795, an α7nAChR partial agonist, blocks the Aβ~42~-α7nAChR interaction, Aβ~42~ internalization into neuronal cells, and Aβ~42~-induced tau phosphorylation \[[@CR4], [@CR5]\]. The critical role of α7nAChR in the Aβ-driven AD pathogenesis and cognitive deficits is further substantiated by the report showing that deletion of the α7nAChR gene reduces cognitive deficits and synaptic pathology in a mouse model of AD \[[@CR6]\]. Despite evidence of increased Aβ~42~-α7nAChR complex levels in lymphocytes from AD subjects \[[@CR7]\], it remains ambiguous whether an increased Aβ~42~-α7nAChR complex level in lymphocytes may be a reliable AD biomarker. It is also unknown whether an increase in Aβ~42~-α7nAChR complexes is related to the apolipoprotein E (*APO*E) genotype, especially the ε4 subclass that is regarded as a prominent genetic risk factor for AD \[[@CR8]\].

ApoE regulates lipid metabolism and cholesterol transport in the brain. Among three apoE isoforms, apoE4 is the least metabolically stable and is a recognized risk factor for developing both familial and late-onset sporadic AD by promoting various neuropathological effects \[[@CR9], [@CR10]\]. Proteolytic fragments of apoE are elevated in AD brains \[[@CR11]\] and some synthetic apoE fragments are neurotoxic \[[@CR12], [@CR13]\]. In a postmortem brain study, apoE4 was strongly correlated with vascular Aβ deposition and Aβ plaque density \[[@CR14]\]. Biochemical, cell biological, and transgenic animal studies have indicated that apoE4 can promote AD pathogenesis by altering Aβ deposition and clearance to increase intraneuronal Aβ accumulation and plaque formation \[[@CR15]--[@CR19]\]. ApoE negatively affects the redox system \[[@CR20]\], signaling cascades and Ca^2+^ homeostasis in neurons \[[@CR21], [@CR22]\] as well as cytoskeletal structure and function \[[@CR23], [@CR24]\], but it enhances tau phosphorylation and consequent formation of neurofibrillary tangles (NFTs) \[[@CR25]--[@CR28]\]. However, the underlying mechanisms responsible for these apoE4-mediated deteriorating effects and the cause-effect relationships remain largely unclear.

More recently, apoE low-density lipoprotein (LDL) receptor binding domain-containing peptide fragments were shown to inhibit α7nAChRs by interacting directly with the receptors \[[@CR29]--[@CR31]\]. α7nAChR ligands and Aβ~12--28~, the α7nAChR binding domain of Aβ~42~, all reduce the Aβ~42~-α7nAChR association \[[@CR5], [@CR32], [@CR33]\], and Aβ~42~ promotes tau phosphorylation via activating α7nAChRs \[[@CR3], [@CR5], [@CR7]\]. We therefore examined the effects of these apoE fragments, and more importantly the apoE subtypes, on the Aβ~42~-α7nAChR interaction and on the consequent Aβ~42~-induced, α7nAChR-dependent tau phosphorylation.

Since *APO*E ε4 is a prominent late-onset AD risk factor, the Aβ~42~-α7nAChR complexes in lymphocytes derived from patients enrolled in the CL2-NEURO-003 study (ROSAS cohort) \[[@CR34]\] with diverse *APO*E genotypes who gave blood samples at two time-points at least 1 year apart were examined to determine whether Aβ~42~-α7nAChR complexes in lymphocytes are correlated with *APO*E genotype (*APO*E ε4 specifically). Our results indicate that apoE4 increases the abundance of Aβ~42~-α7nAChR complexes in the brain and lymphocytes. More importantly, we show that exogenous Aβ~42~ increases Aβ~42~-α7nAChR complex levels in lymphocytes of controls and subjects with mild cognitive impairment (MCI) to the heightened levels of AD lymphocytes. Hence, we explored whether the elevated Aβ~42~-α7nAChR complex levels and the magnitude of reduction by exogenous Aβ~42~ in promoting the Aβ~42~-α7nAChR association (reflected by +Aβ~2~/-Aβ~42~ ratios) may be used as AD diagnostic biomarkers that depict the severity of AD pathologies.

Methods {#Sec2}
=======

Materials and chemicals {#Sec3}
-----------------------

HISTOPAQUE-1077, Leupeptin, aprotinin, phenylmethylsulfonyl fluoride (PMSF), pepstatin A, soybean trypsin inhibitor, NaF, sodium vanadate, β-glycerophosphate, 2-mercaptoethanol, NMDA, glycine, Tween-20, and NP-40 were all purchased from Sigma. Aβ~1--42~ was obtained from Invitrogen. Biotinated Aβ~1--42~ and FITC-conjugated Aβ~1--42~ were obtained from Anaspec (San Jose, CA, USA). Anti-α7nAChR (SC-5544, SC-58607), CHRFAM7A (SC-133458), -actin (SC-7210) and -β-actin (SC-47778) were all purchased from Santa Cruz biotechnology. Anti-Aβ~42~ antibody (Ab5078P) was purchased from EMD Millipore. Reacti-Bind™ NeutrAvidin™ High binding capacity coated 96-well plates, covalently conjugated protein A/G-agarose beads, Pierce cell surface protein isolation kit, antigen elution buffer, and chemiluminescent reagents were purchased from Pierce Thermo Scientific. Recombinant human apoE2 (\#350-12), apoE3 (\#350-02), and apoE4 (\#350-04) that produced in *E. coli* (\>90% purity) were purchased from Peprotech. Aβ~1--42~ peptide (trifluoroacetic acid; TFA salt) was dissolved in 50 mM Tris, pH 9.0 containing 10% dimethyl sulfoxide (DMSO) and stored at --80 °C. Biotinated Aβ~1--42~ and fluorescein isothiocyanate (FITC)-conjugated Aβ~1--42~, both ammonium salts, were dissolved in 50 mM Tris, pH 8.0 containing 10% DMSO and stored at --80 °C. All test agents were made fresh according to the manufacturer's recommendation. If DMSO was used as the solvent, the highest DMSO concentration in the incubation medium was 1%.

LDL receptor binding domain of apoE {#Sec4}
-----------------------------------

Six apoE LDL receptor binding domain-containing peptide fragments that showed differential α7nAChRs inhibition \[[@CR29]--[@CR31]\] were synthesized and dissolved in 10% DMSO containing 50 mM Tris HCl, pH 8.8. These peptides were amide-capped at the carboxyl terminus and acetylated at the amino terminus, except for apoE~133--140~ which has a free amino terminus.apoE~133--149~: LRVRLASHLRKLRKRLL apoE~133--149~ (K → L): LRVRLASHLRLLRLRLLapoE~141--148~ scrambled: RLKKLRLR apoE~133--140~: LRVRLASHapoE~141--148~: LRKLRKRL apoE~141--148~ (K → E): LRELRERL

Animals {#Sec5}
-------

Eight- to 10-week-old male Sprague-Dawley rats from Taconic (Germantown, NY, USA) were maintained on a 12-h light/dark cycle with food and water ad libitum. Rats were rapidly decapitated and brain frontal cortices (FCXs) were extracted on ice immediately.

All animal procedures comply with the National Institutes of Health Guide for Care Use of Laboratory Animals and were approved by the City College of New York Animal Care and Use Committee (IACUC), Protocol No. 836.1.

Clinical samples {#Sec6}
----------------

AD and MCI patients as well as control subjects were selected from the population of the ROSAS cohort (CL2-NEURO-003 study, sponsored by SERVIER laboratories, performed at Alzheimer's Disease Research and Clinical Center, Inserm U1027, Toulouse University Hospital, Toulouse, France). Human participants and their informed caregiver took part in the study on a voluntary basis, and they gave their written informed consent at selection. The ethics committee of Toulouse University Hospital approved the study protocol and all its amendments (registration number DGS 20060500).

Four hundred and eight (408) subjects aged 65 years and older were enrolled in the study, and they were divided into three groups and followed for 4 years: 110 normal controls (Mini-Mental State Examination (MMSE) ≥26, Clinical Dementia Rating (CDR) = 0); 100 patients with memory impairment without dementia (MCI; MMSE ≥24, CDR = 0.5, memory impairment (Rey Auditory Verbal Learning Test (RAVLT), but not Diagnostic and Statistical Manual of Mental Disorders, version IV (DSM IV) criteria for AD); and 196 patients with dementia of the Alzheimer's type (AD; 12 ≤ MMSE ≤ 26, CDR ≥0.5, DSM IV criteria). Participants and their informed caregiver participated on a voluntary basis, and gave their written informed consent at inclusion. The ethics committee of Toulouse University Hospital approved the study protocol. For details, see de Mauleon et al. \[[@CR34]\].

Selection of *APO*E genotype subpopulations {#Sec7}
-------------------------------------------

We selected patients and their matched controls from four of the most represented *APO*E genotypes: *APO*E ε2/ε3, *APO*E ε3/ε3, *APO*E ε3/ε4, and *APO*E ε4/ε4. Within each of the four *APO*E genotypes selected, AD and MCI patients as well as controls must have at least two sets of plasma and blood 'buffy coat' samples taken 1 year apart (e.g., at visit M0 and M12 or M12 and M24 that are designated as visit 1 and visit 2). The potential study subjects were then selected and matched according to their age, gender, and level of education using a SAS® iterative algorithm. In each triad/pair selected, the absolute difference between the youngest and the oldest must not exceed 5 years.

A total of 86 subjects including 24 controls (11 females/13 males, 77.91 ± 0.86 years), 30 MCI (19 females/11 males, 77.53 ± 0.84 years), and 32 AD (18 females/14 males, 77.38 ± 0.80 years) patients, paired per age, level of education, and gender for the four most represented genotypes. The *APO*E ε2/ε3 group has 5 AD (3 females/2 males, 78.20 ± 2.62 years), 3 MCI (1 female/2 males, 81.67 ± 1.21 years), and 5 control (1 female/4 males, 78.40 ± 3.21 years) subjects. The ApoE3/E3 group has 10 AD (7 females/3 males, 79.00 ± 1.08 years), 10 MCI (6 females/4 males, 79.00 ± 1.08 years), and 10 control (7 females/3 males, 79.00 ± 1.08 years) subjects, the ApoE3/E4 group has 10 AD (5 females/5 males, 76.80 ± 1.37 years), 10 MCI (4 females/6 males, 77.00 ± 1.30 years), and 9 control (3 females/6 males, 76.44 ± 1.49 years) control subjects, and the ApoE4/E4 group has 10 AD (3 females/4 males, 75.29 ± 2.16 years) and 10 MCI (1 female/6 males, 74.43 ± 2.05 years) subjects.

Preparation of the synaptosomes {#Sec8}
-------------------------------

Rats were sedated by CO~2~ inhalation and killed by decapitation. FCXs were immediately dissected, homogenized, and processed immediately after harvesting to obtain synaptosomes (P2 fraction), as described previously \[[@CR3]\] for neuropharmacological assessments. Synaptosomes were washed twice and suspended in 2 ml ice-cold oxygenated Krebs-Ringer (K-R), containing (in mM): 25 HEPES, pH 7.4, 118 NaCl, 4.8 KCl, 25 NaHCO~3~, 1.3 CaCl~2~, 1.2 MgSO~4~, 1.2 KH~2~PO~4~, 10 glucose, 0.1 ascorbic acid, and a mixture of protease and protein phosphatase inhibitors (Roche Diagnostics) that had been aerated for 10 min with 95% O~2~/5% CO~2~. The protein concentration was determined using the Bradford method (Bio-Rad).

Preparation of the lymphocytes {#Sec9}
------------------------------

Lymphocytes were prepared from blood 'buffy coat' samples using Histopaque 1077 (Sigma) according to the manufacturer's instruction \[[@CR7]\]. Briefly, blood 'buffy coat' (approximately 250 μl) were layered onto 250 μl HISTOPAQUE-1077 at 25 °C. The entire contents were centrifuged at 400 × g for 30 min at 25 °C to obtain the lymphocyte-free plasma (top layer) and opaque interface containing lymphocytes. The lymphocytes were mixed with 1 ml of oxygenized K-R and then centrifuged at 250 × g for 10 min twice. The resultant lymphocyte pellet was resuspended in 250 μl oxygenized K-R and used as the tissue source for the assessment of the Aβ42-α7nAChR complex level. The protein contents of the lymphocyte suspension were estimated using the Bradford method (Bio-Rad).

Ex vivo Aβ~42~ treatment and determination of Aβ~42~-α7nAChR association {#Sec10}
------------------------------------------------------------------------

To test the effect of the ApoE subtype on the Aβ42-α7nAChR interaction, rat cortical synaptosomes (200 μg) were incubated either simultaneously at 37 °C with 0.1 μM Aβ~42~ and 0.01--100 μM of apoE fragments, or with ApoE isoforms for 10 min and then 30 min following the addition of 0.1 μM Aβ~42~. To assess the impact of ApoE in plasma from human subjects as a bioassay, 200 μg of rat cortical synaptosomes were incubated at 37 °C with K-R, 0.1 μM Aβ~42~ or 0.1 μM Aβ~42~ + 25 μl of plasma for 30 min. In a separate set of experiments, human lymphocytes (200 μg) were incubated at 37 °C with K-R or 0.1 μM Aβ~42~ for 30 min (total incubation volume: 250 μl). The reaction was terminated by adding ice-cold Ca^2+^-free K-R containing protease and protein phosphatase inhibitors and centrifuged. The obtained synaptosomes or lymphocytes were homogenized in 250 μl ice-cold immunoprecipitation buffer containing 25 mM HEPES, pH 7.5, 200 mM NaCl, 1 mM EDTA, 0.2% 2-mercaptoethanol, and protease and protein phosphatase inhibitors by sonication for 10 s on ice and solubilized by nonionic detergents: 0.5% NP-40/0.2% Na cholate/0.5% digitonin for 60 min (4 °C) with end-to-end rotation. The obtained lysate was cleared by centrifugation at 20,000 × g for 30 min (4 °C) and the resultant supernatant (0.25 ml) was diluted fourfold with 0.75 ml immunoprecipitation buffer. The Aβ~42~-α7nAChR complexes were immunoprecipitated with immobilized anti-Aβ~42~ antibodies on protein A-conjugated agarose beads. The resultant immunocomplexes were pelleted by centrifugation (4 °C), washed three times with ice-cold phosphate-buffered saline (PBS), pH 7.2, containing 0.1% NP-40, and centrifuged. The resultant immunocomplexes were solubilized by boiling for 5 min in 100 μl SDS-PAGE sample preparation buffer (62.5 mM Tris-HCl, pH 6.8; 10% glycerol, 2% SDS; 5% 2-mercaptoethanol, 0.1% bromophenol blue) and centrifuged to remove antibody-protein A/G agarose beads. The contents of α7nAChRs and actin were determined by Western blotting with the level of actin serving as the indicator of immunoprecipitation efficiency and gel loading \[[@CR4], [@CR5], [@CR7]\].

Determination of CHRFAM7A-α7nAChR association in membranes of lymphocytes {#Sec11}
-------------------------------------------------------------------------

To assess the association of CHRFAMA7 and α7nAChR on the lymphocyte membranes, lymphocytes (200 μg) obtained from ROSAS cohort were ruptured by sonicated on ice in 250 μl hypotonic lysis buffer containing (in mM): 25 HEPES, pH 7.4, 11.8 NaCl, 0.48 KCl, 2.5 NaHCO~3~, 0.13 CaCl~2~, 0.12 MgSO~4~, 0.12 KH~2~PO~4~, and a mixture of protease and protein phosphatase inhibitors. Following centrifugation at 50,000 × g for 30 min at 4 °C, the resultant lymphocytic cell membranes were homogenized by sonication for 10 s on ice and solubilized by nonionic detergents: 0.5% NP-40/0.2% Na cholate/0.5% digitonin for 60 min (4 °C) with end-to-end rotation. The resultant lysate was cleared of debris by centrifugation at 20,000 × g for 30 min (4 °C) and the resultant supernatant (0.25 ml) was diluted fourfold with 0.75 ml immunoprecipitation buffer. The Aβ~42~-α7nAChR complexes were then immunoprecipitated with immobilized anti-CHRFAM7A on protein A-conjugated agarose beads. The resultant immunocomplexes were pelleted by centrifugation (4 °C), washed three times with ice-cold 0.1% NP-40 containing PBS, and centrifuged. The resultant immunocomplexes were solubilized by boiling for 5 min in 100 μl SDS-PAGE sample preparation buffer and then centrifuged to remove antibody-protein A agarose beads. The abundance of α7nAChRs in the anti-CHRFAM7A immunoprecipitate was determined by Western blotting with anti-α7nAChR (SC-58607). The blot was then stripped, blocked with 10% nonfat milk containing 0.1% PBST for 1 h and incubated with anti-CHRFAM7A overnight at 4 °C to validate equal efficiency of the immunoprecipitation and gel loading.

Western blot analysis {#Sec12}
---------------------

Solubilized immunoprecipitates size-fractionated by 10% or 10--16% SDS-PAGE was electrophoretically transferred to nitrocellulose membranes. The membranes were washed with PBS three times and blocked overnight (4 °C) with 10% milk in 0.1% Tween-20-containing PBS (PBST). The membranes were washed with 0.1% PBST three times, incubated at 25 °C for 2 h or at 4 °C overnight with 1:500--1:1000 dilutions of selected antibodies including (α7nAChR (SC-58607), β-actin (SC-47778), and CHRFAM7A (SC-133458). After three 0.1% PBST washes, membranes were incubated for 1 h with anti-species IgG-HRP (1:5000--7500 dilution) and washed three times with 0.1% PBST (2 min each). The signals were detected using a chemiluminescent method and visualized by exposure to X-ray film. Specific bands were quantified by densitometric scanning (GS-800 calibrated densitometer; Bio-Rad).

In vitro assessment of Aβ~42~-α7nAChR and Aβ~42~-Aβ~42~ interaction {#Sec13}
-------------------------------------------------------------------

The effect of apoE fragments and ApoE isoform on Aβ~42~-α7nAChR interaction was measured in vitro with 2 nM biotinated α7nAChRs trapped on streptavidin-coated plate (Reacti-Bind™ NeutrAvidin™ High binding capacity coated 96-well plate; Pierce). Biotinylation of the cell surface proteins was performed using the Pierce cell surface protein isolation kit according to the manufacturer's protocol. Briefly, T75 cm^2^ flasks of 95% confluent SK-N-MC cells were quickly washed with ice-cold PBS. Biotinylation of the cell surface proteins was performed using sulfo-NHS-SS-Biotin. Following termination of the reaction, cells were scraped into PBS and collected by centrifugation. The cells were then lyzed by brief sonication and centrifuged to obtain cell membranes. The resultant cell membranes were solubilized using 0.5% NP-40/0.2% sodium cholate/0.5% digitonin. The biotinylated α7nAChRs were isolated by immunoaffinity column with immobilized anti-α7nAChR antibodies. The plate was washed, blocked with 20% superblock (Pierce-Thermo), and incubated with K-R or 0.01--100 μM apoE fragments for 10 min followed by 60 min with 20 nM FITC-tagged Aβ~42~ at 30 °C. The plate was washed extensively and the residual FITC-Aβ~42~ signals were determined by multimode plate reader (DTX880; Beckman).

The effect of apoE fragments on Aβ~42~-α7nAChR interaction was measured in vitro with 2 nM biotinated Aβ~42~ trapped on streptavidin-coated 96-well plate, washed, and incubated with 0.01--100 μM of apoE fragments for 10 min prior to incubation with 20 nM FITC-tagged Aβ~42~ for 60 min at 30 °C. The plate was then washed five times with 50 mM Tris HCl, pH 7.5. The FITC-Aβ~42~ signals were detected using a multi-mode plate reader (DTX-880). Negligible FITC-Aβ~42~ was noted when either biotinated Aβ~42~ peptides or α7nAChRs were omitted.

Ex vivo determination of Aβ~42~-induced tau phosphorylation {#Sec14}
-----------------------------------------------------------

The effect of apoE fragments on Aβ~42~-induced tau phosphorylation was examined using experimental procedure described previously \[[@CR3], [@CR5], [@CR7]\]. Briefly, well-washed rat FCX synaptosomes (500 μg) were incubated in oxygenated K-R with 0.01--100 μM apoE fragment and/or 0.1 μM Aβ~42~ at 37 °C for 30 min. The total tau proteins were immunoprecipitated with anti-tau and the phosphorylated serine^202^-tau (pS^202^tau), threonine^231^-tau (pT^231^tau), and threonine^181^-tau (pT^181^tau) contents were determined by Western blotting (Pierce-Thermo).

Statistical analyses {#Sec15}
--------------------

All data are presented as mean ± standard error from the mean (SEM). Treatment effects were evaluated by analysis of variance (ANOVA). Specifically, the apoE fragment and subtype effects of the Aβ~42~-α7nAChR association and tau phosphorylation in animal experiments were evaluated using one-way ANOVAs followed by Newman-Keul's for multiple comparisons.

To analyze the biochemical data in the human studies, a mixed linear model was used (with pairing identifier as a random effect) in order to test paired differences among the three diagnostic groups as well as among the four ApoE genotypes. *P* values were corrected for multiple testing using the Dunnett's approach. The threshold for significance was *p* \< 0.05.

Correlations between criteria were evaluated using the Spearman correlation coefficient (with 95% confidence interval). SAS 9.2 and R 3.1.2 software were used to perform these analyses.

Results {#Sec16}
=======

Selective apoE LDL receptor binding domain fragments enhance the Aβ~42~-α7nAChR association {#Sec17}
-------------------------------------------------------------------------------------------

To evaluate the effect of apoE LDL receptor binding domain fragments on the Aβ~42~-α7nAChR association, rat FCX synaptosomes were incubated with 0.1--100 μM apoE LDL receptor binding domain fragments either 10 min prior to, or simultaneously with, 0.1 μM Aβ~42~. This sequence is identical in the three human isoforms (E2, E3, and E4) of apoE protein. Lysates from Aβ~42~-incubated synaptosomes were immunoprecipitated with immobilized anti-Aβ~42~ antibodies and the Aβ~42~-associated α7nAChR levels were determined by Western blotting. Our ex vivo data as summarized in Fig. [1](#Fig1){ref-type="fig"} indicate that ApoE~133--149~ peptide added in vitro simultaneously or 10 min prior to Aβ~42~ increased the abundance of Aβ~42~-α7nAChR complexes by 21.8 ± 6.4 to 39.7 ± 6.8% and 30.8 ± 7.4 to 45.4 ± 9.5%, respectively, with subtle dose dependency indicated by a 14.0 ± 1.8% increase by simultaneous addition of 0.05 μM apoE fragments with Aβ~42~ (Fig. [1](#Fig1){ref-type="fig"}). Addition of apoE~141--148~ in vitro simultaneously or 10 min prior to Aβ~42~ increased the abundance of Aβ~42~-α7nAChR complexes by 21.9 ± 6.2 to 27.0 ± 5.6% and 18.7 ± 6.0 to 33.2 ± 10.3%, respectively, with slight dose-dependency as indicated by a 14.5 ± 4.4% increase by simultaneous addition of 0.05 μM apoE with Aβ~42~ (Fig. [1](#Fig1){ref-type="fig"}). Substitution of lysine to leucine or aspartate residues in apoE~133--149~ and ApoE~141--148~, respectively, and scrambled apoE~141--148~ eliminated the effect of apoE~133--149~ and apoE~141--148~ on the Aβ~42~-α7nAChR interaction (Fig. [1a and b](#Fig1){ref-type="fig"}). In contrast, similar incubation of the rat FCX synaptosomes with apoE~133--140~ did not alter the Aβ~42~-α7nAChR association (Fig. [1a and b](#Fig1){ref-type="fig"}). The comparable β-actin levels in anti-Aβ~42~/actin immunoprecipitates demonstrated equal immunoprecipitation efficiencies and loading.Fig. 1ApoE~141--148~ mediates apoE-induced Aβ42-α7nAChR association enhancement ex vivo in rat brain synaptosomes. Rat frontal cortical synaptosomes were incubated with 0.1--100 μM apoE either 10 min prior to or simultaneously with 0.1 μM Aβ~42~. Synaptosomes were collected by centrifugation, solubilized, and immunoprecipitated with anti-Aβ~42~. The level of Aβ~42~-associated α7nAChRs in anti-Aβ~42~ antibody immunoprecipitates was shown by Western blot detection of α7nAChR **a** and quantified by densitometric scanning (**b**). Separately, rat cortical synaptosomes were incubated with 0.01, 0.05, 0.1, 1, and 10 nM of apoE~133--149~ or apoE~141--148~ simultaneously with 0.1 μM Aβ~42~. The level of Aβ~42~-associated α7nAChRs in anti-Aβ~42~ antibody immunoprecipitates was demonstrated by Western blot detection of α7nAChR and quantified by densitometric scanning (**c**). \**p* \< 0.01, compared to Aβ~42~ alone by Newman-Keuls multiple comparisons (*n* = 5). *α7nAChR* α7-nicotinic acetylcholine receptor, *Aβ* amyloid beta, *ApoE* apolipoprotein E, *IP* immunoprecipitation

The effects of the apoE LDL receptor binding domain fragments on the Aβ~42~-α7nAChR interaction were verified using a cell-free assay system with biotinylated α7nAChRs trapped on a streptavidin-coated plate \[[@CR4]\]. As in the ex vivo experiments described above, the ApoE fragments were added simultaneously with, or 10 min prior to, 20 nM FITC-conjugated Aβ~42~. The level of Aβ~42~-α7nAChR association was measured by the residual FITC signals. The data summarized in Fig. [2](#Fig2){ref-type="fig"} indicate that 0.01--100 μM apoE~133--149~ added in vitro either simultaneously with or 10 min prior to Aβ~42~ increased the level of Aβ~42~-α7nAChR complexes by 13.8 ± 5.7 to 94.1 ± 17.2% and 13.9 ± 5.3 to 84.0 ± 16.7%, respectively (Fig. [2](#Fig2){ref-type="fig"}). Similarly, the addition of 0.01--100 μM apoE~141--148~ in vitro both simultaneously and 10 min prior to Aβ~42~ increased the abundance of Aβ~42~-α7nAChR complexes by 34.2 ± 7.6 to 105.8 ± 12.3% and 28.1 ± 6.1 to 90.0 ± 12.5%, respectively (Fig. [2](#Fig2){ref-type="fig"}). In contrast, substitution of lysine to leucine or aspartate residues in apoE~133--149~ and apoE~141--148~, respectively, and scrambled apoE~141--148~ had no effect on the Aβ~42~-α7nAChR interaction (Fig. [2](#Fig2){ref-type="fig"}). The addition of apoE~133--140~ also did not alter Aβ~42~-α7nAChR interaction.Fig. 2ApoE~141--148~ mediates apoE-induced Aβ~42~-α7nAChR association enhancement in vitro in a cell-free system. In vitro assessment of the effect of 0.01--100 μM apoE fragments on the Aβ~42~-α7nAChR interaction in biotin-tagged α7nAChRs trapped on a streptavidin-coated 96-well plate. The apoE fragments were added simultaneously with **a** or 10 min prior to **b** 20 nM FITC-conjugated Aβ~42~. The level of Aβ~42~-α7nAChR association was measured by the residual FITC signals. The data are mean ± SEM of the percentage change from vehicle-treated wells (*n* = 6). \**p* \< 0.01, \*\**p* \< 0.05, compared to vehicle control by Newman-Keuls multiple comparisons. *ApoE* apolipoprotein E

Effects of apoE LDL receptor binding domain fragments on Aβ~42~-Aβ~42~ association {#Sec18}
----------------------------------------------------------------------------------

To assess the possibility that apoE increases the Aβ~42~-α7nAChR complex level by facilitating Aβ~42~ already bound to α7nAChR, we determined the effects of various apoE LDL receptor binding domain fragments on the Aβ~42~-Aβ~42~ association using an established cell-free system with biotinylated Aβ~42~ trapped on a streptavidin-coated plate \[[@CR4]\]. The biotin-tagged Aβ~42~ trapped streptavidin-coated 96-well plate was incubated with 0.1--100 μM apoE fragments for 10 min prior to the addition of 20 nM FITC-conjugated Aβ~42~. The results shown in Fig. [3](#Fig3){ref-type="fig"} indicate that all six apoE LDL receptor binding domain fragments at concentrations up to 100 μM have negligible effects on the Aβ~42~-Aβ~42~ complex formation. These data suggest that apoE promotes Aβ~42~-α7nAChR interaction directly but not by facilitating Aβ~42~ binding to Aβ~42~ already associated with the α7nAChRs.Fig. 3ApoE fragments do not affect Aβ~42~-Aβ~42~ interaction in vitro. Biotin-tagged Aβ~42~ trapped streptavidin-coated 96-well plate was incubated with 0.1--100 μM apoE fragments for 10 min prior to the addition of 20 nM FITC-conjugated Aβ~42~. The level of Aβ~42~-Aβ~42~ complexes was measured by the residual FITC signals. The data are mean ± SEM of percentage change from vehicle-treated wells (*n* = 6). The apoE fragments did not alter the Aβ~42~-Aβ~42~ association. The dose-response curve for each peptide was analyzed using one-factor ANOVA. There is no statistical significance observed. *ApoE* apolipoprotein E

ApoE4 increases the Aβ~42~-α7nAChR association {#Sec19}
----------------------------------------------

Because *APO*E ε4 is a prominent late-onset AD risk factor and all apoE subtypes contain the LDL receptor binding domain, we assessed whether different apoE subtypes differentially modulate the Aβ~42~-α7nAChR association. We used both in vitro and ex vivo methods. In the in vitro experimental paradigm, the biotinylated α7nAChR trapped streptavidin-coated plate was incubated with 0.01--100 nM recombinant human apoE isoforms in the presence of FITC-conjugated Aβ~42~. ApoE4 at the test concentrations increased the Aβ~42~-α7nAChR association by 17.9 ± 2.1 to 60.2 ± 6.3% (Fig. [4a](#Fig4){ref-type="fig"}); apoE3 promoted a much weaker enhancement of the Aβ~42~-α7nAChR interaction at 10 nM that did not reach statistical significance (13.6 ± 7.9% increase; Fig. [4a](#Fig4){ref-type="fig"}). Next, rat FCX synaptosomes were incubated with 0.01--10 μM of recombinant human apoE subtypes in the presence of Aβ~42~. ApoE4 at 0.1--10 μM increased the abundance of Aβ~42~-α7nAChR complexes by 34.9 ± 5.4 to 72.6 ± 8.7%, whereas apoE2 and apoE3 were without significant effects (Fig. [4b and c](#Fig4){ref-type="fig"}). The comparable β-actin levels in anti-Aβ~42~/actin immunoprecipitates demonstrated equal immunoprecipitation efficiencies and loading. These data together indicate that apoE4 can enhance the formation of Aβ~42~-α7nAChR complexes.Fig. 4ApoE4 preferentially increases the Aβ~42~-α7nAChR interaction. Biotin-tagged α7nAChRs trapped streptavidin-coated 96-well plate was incubated with 0.01--100 nM of recombinant apoE subtypes for 10 min prior to addition of 20 nM FITC-conjugated Aβ~42~. The effect of apoE subtype on the Aβ~42~-α7nAChRs interaction was determined by the residual FITC signals (**a**). Rat frontal cortical synaptosomes were incubated with 0.01--10 μM of recombinant apoE subtypes and/or 0.1 μM Aβ~42~. Synaptosomes were collected by centrifugation, solubilized, and immunoprecipitated with anti-Aβ~42~ antibodies. The level of Aβ~42~-associated α7nAChRs in anti-Aβ~42~ immunoprecipitates was shown by Western blot detection of α7nAChR **b** and quantified by densitometric scanning (**c**). \**p* \< 0.01, \*\**p* \< 0.05, compared to Aβ~42~ alone by Newman-Keuls multiple comparisons (*n* = 4--8). *α7nAChR* α7-nicotinic acetylcholine receptor, *Aβ* amyloid beta, *ApoE* apolipoprotein E, *IP* immunoprecipitation

Specific apoE LDL receptor binding domain fragments increases Aβ~42~-induced tau phosphorylation {#Sec20}
------------------------------------------------------------------------------------------------

Aβ~42~ (0.1 μM) increased pS^202^tau, pT^231^tau, and pT^181^tau by 450--703% within 30 min in FCX synaptosomes (Fig. [5a and b](#Fig5){ref-type="fig"}). Because apoE LDL receptor binding domain fragments that contain apoE~141--148~ promote Aβ~42~-α7nAChR interaction, we assessed their effects on Aβ~42~-induced, α7nAChR-dependent tau phosphorylation. Just as apoE~141--148~ containing peptides (apoE~133--149~ and apoE~141--148~) increased the Aβ~42~-α7nAChR interaction, incubation of apoE~133--149~ or apoE~141--148~ enhanced Aβ~42~-induced tau phosphorylation at all three phosphoepitope levels with similar efficacy. Densitometric quantification reveals that apoE~133--149~ and apoE~141--148~ increased Aβ~42~-induced pS^202^tau, pT^231^tau, and pT^181^tau levels by 19.9 ± 5.7 to 52.3 ± 9.3% and 26.3 ± 7.1 to 40.8 ± 9.4%, respectively (Fig. [5a and b](#Fig5){ref-type="fig"}). Again, apoE~133--149~ with lysine to leucine substitution and apoE~141--148~ with lysine to aspartate substitution, as well as scrambled apoE~141--148~, had no effect on Aβ~42~-induced tau phosphorylation (Fig. [5a and b](#Fig5){ref-type="fig"}). Similar incubation of the rat FCX synaptosomes with apoE~133--140~ did not have appreciable effects on Aβ~42~-induced phosphorylation at all three tau phosphoepitopes (Fig. [5a and b](#Fig5){ref-type="fig"}). The dose-dependency of apoE~133--149~ and apoE~141--148~ in promoting Aβ~42~-induced tau phosphorylation was further tested by simultaneous addition of 0.01--10 μM apoE~133--149~ and apoE~141--148~ with Aβ~42~. Similar to their effects on the Aβ~42~-α7nAChR association, apoE~133--149~ and apoE~141--148~ significantly increased Aβ~42~-induced tau phosphorylation on Serine^202^, Threonine^231^, and Threonine^181^ by 20.5 ± 5.3 to 54.9 ± 13.0% and 29.5 ± 6.7 to 62.3 ± 10.2%, respectively, starting at 0.05 μM (Fig. [5c](#Fig5){ref-type="fig"}). These data together confirm that the apoE4 isoform can promote Aβ-induced neurofibrillary lesions via the apoE~141--148~ region.Fig. 5ApoE~141--148~ mediates ApoE-induced Aβ~42~-elicited α7nAChR-dependent tau phosphorylation. Rat frontal cortical synaptosomes were incubated simultaneously with 0.1--100 μM apoE fragments and 0.1 μM Aβ~42~. Synaptosomes were collected by centrifugation, solubilized, and immunoprecipitated with anti-tau antibodies. The levels of Aβ~42~-induced tau phosphorylation on the serine 202 (*pS* ^*202*^ *tau*), threonine181 (*pT* ^*181*^ *tau*), and threonine231 (*pT* ^*231*^ *tau*) in anti-tau immunoprecipitates shown were determined using Western blot detection of each phosphoepitope **a** and quantified by densitometric scanning (**b**). Separately, rat cortical synaptosomes were incubated with 0.01, 0.05, 0.1, 1, and 10 nM apoE~133--149~ or apoE~141--148~ simultaneously with 0.1 μM Aβ~42~. The level of Aβ~42~-induced pS^202^tau, pT^181^tau, and pT^231^tau in anti-tau immunoprecipitates were determined by Western blot detection of each phosphoepitope and quantified by densitometric scanning (**c**). \**p* \< 0.01, \*\**p* \< 0.05, compared to Aβ~42~ alone by Newman-Keuls multiple comparisons (*n* = 4--6). *Aβ* amyloid beta, *ApoE* apolipoprotein E, *IP* immunoprecipitation

Increased Aβ~42~-α7nAChR association by plasma from patients with dementia due to AD and MCI subjects {#Sec21}
-----------------------------------------------------------------------------------------------------

The parallel increases in Aβ~42~-α7nAChR complex formation and Aβ~42~-induced tau phosphorylation by the fragments containing apoE~141--148~ suggest that apoE4 can facilitate AD pathogenesis by promoting the Aβ~42~-α7nAChR interaction. Previously, we have shown in synaptosomes derived from rodent and human postmortem brains that incubation of synaptosomes with exogenous Aβ~42~ promotes the formation of Aβ~42~-α7nAChR complexes to the levels of AD \[[@CR4], [@CR5], [@CR7]\]. Using an ex vivo system, we determined the magnitude of the increase in the Aβ~42~-α7nAChR association induced by incubating rat FCX synaptosomes simultaneously with 0.1 μM Aβ~42~ and 25 μl plasma from patients of the ROSAS cohort with diverse *APO*E genotypes. Our data show that the Aβ~42~-α7nAChR complexes were more abundant when incubated with plasma from subjects with MCI (increased by 44.7 ± 6.7%) and AD (increased by 99.5 ± 3.6%) compared to plasma from controls (increased by 13.5 ± 4.1%) regardless of *APO*E genotypes in visit 1 (Fig. [6a and b](#Fig6){ref-type="fig"}). There were no discernible differences between visit 1 and the follow-up visit 2 (Fig. [6a and b](#Fig6){ref-type="fig"}). Using the percentage increase by the addition of plasma, our data indicate that apoE4 promotes the Aβ~42~-α7nAChR association: the levels of Aβ~42~-α7nAChR complexes progressively increased as the number of *APO*E ε4 alleles increased in MCI and AD cases (Fig. [6a and c](#Fig6){ref-type="fig"}). A significant correlation was found between the percentage increase by the addition of plasma and total MMSE score with an overall Spearman correlation coefficient of --0.71 (Fig. [6d](#Fig6){ref-type="fig"}). A significant correlation was also noted between the percentage increase and disease progression (reduction of the MMSE score) with an overall Spearman correlation coefficient of --0.57 (Fig. [6e](#Fig6){ref-type="fig"}). This finding is in contrast with *APO*E ε2 and *APO*E ε3 carriers, whose Aβ~42~-α7nAChR complex levels virtually held steady with fewer incidences of cognitive decline. Together, these data support the notion that apoE4 promotes AD pathogenesis by promoting Aβ~42~-α7nAChR complex formation.Fig. 6Enhanced Aβ~42~-α7nAChR association by plasma from *APO*Eε4 carriers with MCI or dementia due to AD correlates with longitudinal cognitive decline. Rat frontal cortical synaptosomes were incubated simultaneously with 25 μl plasma and 0.1 μM Aβ~42~. The levels of Aβ~42~-α7nAChR complexes were determined by the abundance of α7nAChRs in the anti-Aβ~42~ antibody immunoprecipitates by Western blotting (**a**), quantified by densitometric scanning, and normalized by β-actin immunoreactivity as the immunoprecipitation/loading controls. The data expressed as the ratios of positive plasma to negative plasma (mean ± SEM) summarizes the effects of plasma derived from two separate visits on Aβ~42~-elicited the Aβ~42~-α7nAChR association in different diagnostic groups without **b** and with **c** segregating by the *APO*E genotype. \**p* \< 0.01, \*\**p* \< 0.05, compared to respective cognitive normal group **b** or *APO*E ε2/ε3 **c** by Dunnett's test adjusted for multiple comparisons. **d** Correlation to baseline cognitive status defined by Mini-Mental State Examination (*MMSE*) score (*n* = 86): spearman correlation coefficient, controls = 0.19 (--0.23; 0.55); MCI = --0.32 (--0.61; 0.06); AD = --0.14 (--0.46; 0.22); all = --0.71 (--0.80; --0.59). **e** Correlation to longitudinal cognitive changes per evolution of diagnostic group (control not progressed (*CTRL NP*) and progressed (P), MCI NP and P, and AD): spearman correlation coefficient controls NP = --0.19 (--0.58; 0.26); controls P = NA; MCI NP = --0.19 (--0.67; 0.40); MCI P = --0.22 (--0.64; 0.31); AD = --0.30 (--0.58; 0.05); all = --0.57 (--0.70; --0.41). *α7nAChR* α7-nicotinic acetylcholine receptor, *Aβ* amyloid beta, *AD* Alzheimer's disease, *apoE* apolipoprotein, *C* controls, *MCI* mild cognitive impairment, *V* visit

Aβ~42~-α7nAChR complex levels and reduced response to exogenous Aβ~42~ in MCI and AD lymphocytes correlate with plasma apoE4 level {#Sec22}
----------------------------------------------------------------------------------------------------------------------------------

Because lymphocytes contain α7nAChRs and abundant CHRFAM7A and the Aβ~42~-α7nAChR complexes are more abundant in AD \[[@CR7], [@CR35]\], we assessed whether the Aβ~42~-α7-like nAChR complex levels are higher in the membranes of lymphocytes from AD and MCI patients and whether the abundance of Aβ~42~-α7-like nAChR complexes correlate with the *APO*E genotypes, especially the *APO*E ε4. We isolated lymphocytes from the buffy coat of a large cohort consisting of well-matched control-MCI-AD triads with diverse *APO*E genotypes at two time points. We determined the levels of Aβ~42~-α7-like nAChR complexes following ex vivo exposure to either K-R or 0.1 μM Aβ~42~. As reported previously \[[@CR7]\], Aβ~42~-α7-like nAChR complex levels increased following exposure to exogenous Aβ~42~. Exogenous Aβ~42~ increased Aβ~42~-α7-like nAChR complex levels by 143.7 ± 14.8% in controls and by 91.9 ± 13.9% in MCI subjects, but by only 9.4 ± 1.0% in AD patients at visit 1 (Fig. [7a and b](#Fig7){ref-type="fig"}). This Aβ~42~-induced response did not change significantly in lymphocytes obtained at visit 2 (Fig. [7a and b](#Fig7){ref-type="fig"}). Corroborating plasma effects in rat cortical synaptosomes, the levels of Aβ~42~-α7-like nAChR complexes progressively increased along with increasing number of *APO*E ε4 alleles in the MCI and AD cases, as indicated by the reduced effects of exogenously added Aβ~42~ (Fig. [7a and c](#Fig7){ref-type="fig"}). The Aβ~42~-induced increases in Aβ~42~-α7-like nAChR complex levels in lymphocytes were significantly correlated with plasma-elicited increases in Aβ~42~-evoked Aβ~42~-α7nAChR association when segregated by diagnosis (Fig. [7d](#Fig7){ref-type="fig"}). As in rodent synaptosome experiments, a significant correlation was found between the +Aβ~42~/-Aβ~42~ ratios in lymphocytes and the magnitude of decrease in MMSE score with an overall Spearman correlation coefficient of 0.46 (Fig. [7e](#Fig7){ref-type="fig"}). There were, however, no discernible *APO*E genotype- or diagnosis-related changes in α7nAChRs and α7nAChR-like, CHRFAM7A protein levels in lymphocytes in this study cohort (Fig. [8a and b](#Fig8){ref-type="fig"}). Our data also show that α7nAChR and CHRFAM7A do form complexes with each other in the membranes of lymphocytes as indicated by the coimmunoprecipitation of α7nAChR and CHRFAM7A. However, there were no detectable *APO*E ε genotype- or diagnosis-related changes in the α7nAChR/CHRFAM7A complex levels (Fig [8c and d](#Fig8){ref-type="fig"}).Fig. 7Higher Aβ~42~-α7nAChR complex levels and reduced response to exogenous Aβ~42~ in lymphocytes from MCI and AD patients correlate with plasma apoE4. Lymphocytes obtained from cognitive normal controls (*C*), subjects with mild cognitive impairments (*MCI*), and Alzheimer's disease (*AD*) were incubated without or with 0.1 μM Aβ~42~. The levels of Aβ~42~-α7nAChR complexes were determined by the abundance of α7nAChRs in the anti-Aβ~42~ antibody immunoprecipitates by Western blotting (**a**), quantified by densitometric scanning, and normalized by β-actin immunoreactivity as the immunoprecipitation/loading controls. The data expressed as the ratios of positive Aβ~42~ to negative Aβ~42~ (mean ± SEM) summarizes the effects of Aβ~42~ derived from two separate visits on the Aβ~42~-α7nAChR association in different diagnostic groups without **b** and with **c** segregating by the *APO*E genotype. \**p* \< 0.01, \*\**p* \< 0.05, compared to respective cognitive normal group **b** or *APO*E ε2/ε3 **c** by Dunnett's test adjusted for multiple comparisons. **d** Correlations between positive plasma to negative plasma ratios in synaptosomes and positive Aβ~42~ to negative Aβ~42~ ratios in lymphocytes derived from visit 1 spearman correlation coefficient: controls = 0.17 (--0.25;0.54); MCI = --0.81 (--0.91; --0.62); AD = --0.58 (--0.77; --0.30); all = --0.84 (--0.89; --0.76). **e** Correlation to longitudinal cognitive changes per evolution of diagnostic group (control not progressed (*CTRL NP*) and progressed (*P*), MCI NP and P, and AD), *n* = 86 including 32 AD, 30 MCI, and 24 control subjects from four distinct *APO*E genotype groups: controls NP = --0.04 (0.46; 0.40); controls P = NA; MCI NP = --0.08 (--0.61; 0.49); MCI P = --0.10 (--0.57; 0.42); AD = 0.23 (--0.12; 0.53); all = 0.46 (0.28; --0.62). *α7nAChR* α7-nicotinic acetylcholine receptor, *Aβ* amyloid beta, *apoE* apolipoprotein, *V* visit Fig. 8No *APO*E genotype- or diagnosis-related changes in α7nAChR and CHRFAM7A expression levels in lymphocytes. Lymphocytes obtained from cognitive normal controls, subjects with mild cognitive impairments (*MCI*) and Alzheimer's disease (*AD*) were solubilized. The expression levels of α7nAChR and CHRFAM7A, both with apparent molecular mass of 54 kDa, in 50 μg of solubilized lymphocytes along with the loading control, GADPH, are shown by Western blot detection **a** and quantified by densitometric scanning that demonstrates no discernible changes in α7nAChR or CHRFAM7A expression (**b**). Solubilized lymphocyte membranes (200 μg) were used to assess α7nAChR/CHRFAM7A complex levels by immunoprecipitation with immobilized anti-CHRFAM7A and -actin. The abundance of α7nAChR, CHRFAM7A, and β-actin in anti-CHRFAM7A/actin immunoprecipitate is shown by Western blot detection **c** and quantified by densitometric scanning that demonstrates no diagnosis- or *APO*E ε genotype-related changes in α7nAChR, ChRFAM7A, and β-actin levels in lymphocyte membranes (**d**). *n* = 86 including 32 AD, 30 MCI and 24 control subjects from four different APOE genotype groups. *α7nAChR* α7-nicotinic acetylcholine receptor, *ApoE* apolipoprotein E, *IP* immunoprecipitation

Discussion {#Sec23}
==========

The present study shows that apoE4 interacts with α7nAChRs via the apoE LDL receptor binding domain, apoE~141--148~, to increase Aβ~42~-α7nAChR association and Aβ~42~-elicited, α7nAChR-dependent tau phosphorylation. Plasma from *APO*E ε4 carriers increased Aβ~42~-α7nAChR complex levels in rat synaptosomes. The relevance of these in vitro and ex vivo results to AD pathogenesis is supported by higher abundance of Aβ~42~-α7-like nAChR complexes in AD and MCI lymphocytes, correlating with the *APO*E ε4 genotype in hetero- and homozygous *APO*E ε4 carriers. Underscoring the more rapid cognitive decline in *APO*E ε4 carriers, we present a novel mechanism through which apoE4 may facilitate the Aβ~42~-driven AD pathogenesis in both brain and peripheral cells. Conspicuously, plasma from all AD subjects (independent of *APO*E ε4 status) has a greater effect on promoting the Aβ~42~-α7nAChR association, and lymphocytes of AD subjects have more abundant Aβ~42~-α7-like nAChR complexes. These findings suggest that other factor(s) in addition to *APO*E ε4 may be present in AD. Neurotoxic apoE proteolytic products can be formed by neurons in *APO*E ε4 transgenic mice and in the brains and cerebrospinal fluid from AD patients, with the highest level found in *APO*E ε4 carriers \[[@CR11], [@CR27], [@CR36]--[@CR38]\]. Some synthetic apoE fragments are neurotoxic \[[@CR12], [@CR13]\]. Since the neurotoxic apoE fragments retain the LDL binding domain \[[@CR36], [@CR39]\], the increased Aβ~42~-α7nAChR interaction in AD may result from higher apoE toxic fragments that presumably increase with duration of disease, although their presence in the plasma of AD subjects is currently not known.

*APO*E ε4 accelerates the onset of both familial and late-onset sporadic AD with greater deleterious cognition effects and neurodegeneration in women than in men \[[@CR40]--[@CR45]\]. *APO*E ε4 is associated with worse clinical outcome in traumatic brain injury \[[@CR46]\], multiple sclerosis \[[@CR47]\], Parkinson's disease \[[@CR48]\], frontotemporal dementia \[[@CR49]\], and stroke \[[@CR50]\]. ApoE fragments increase NFT-like intraneuronal inclusions in cultured neurons \[[@CR27]\]. Peptide fragments derived from the apoE LDL receptor binding domain interact with, and inhibit, α7nAChR \[[@CR29]--[@CR31]\]. However, these data do not directly support the known apoE4 role in promoting AD pathogenesis, even though α7nAChR is a receptor for Aβ and contributes to Aβ~42~-mediated AD pathologies \[[@CR4]--[@CR7], [@CR32], [@CR33]\]. Our data showing that apoE4 promotes the Aβ~42~-α7nAChR association provides an essential link to AD pathogenesis. This hypothesis is supported by the AD-like neurodegeneration and behavioral deficits in transgenic mice expressing carboxyl-terminal truncated apoE4 \[[@CR36]\]. Although the apoE LDL receptor binding domain is common to all apoE subtypes, recombinant human apoE4 preferentially increases the Aβ~42~-α7nAChR association. This finding suggests that the conformation of apoE4, but not apoE3 or apoE2, exposes the apoE LDL receptor binding domain to α7nAChRs since the amino acid sequences of apoE subtypes are almost virtually identical. This hypothesis is supported by an earlier report that suggests that apoE4 is structurally different from apoE3 based on differences in hydrogen-deuterium exchange and site-directed mutations \[[@CR51]\].

ApoE appears to regulate Aβ aggregation and deposition. Deletion of the *APO*E gene dramatically reduces fibrillar Aβ deposits in an AD transgenic mouse model \[[@CR52]\] as well as apoE immunoreactivity in amyloid plaques in human AD brains \[[@CR53]\]. By increasing the Aβ~42~-α7nAChR association, apoE4 can promote internalization of the Aβ~42~-α7nAChR complexes to facilitate formation of intraneuronal Aβ aggregates and amyloid plaques \[[@CR2]\]. The elevated intraneuronal Aβ oligomers can impair intraneuronal mitochondria and lysosomes to drive neurodegeneration \[[@CR18]\]. In agreement, Aβ-rich amyloid plaques are more abundant and commonly found in *APO*E ε4 carriers and AD patients with positive amyloid scans \[[@CR14], [@CR54]--[@CR56]\]. Increased Aβ~42~-α7nAChR interaction by apoE4 suggests that amyloid plaques may form early and more readily in *APO*E ε4 carriers \[[@CR57], [@CR58]\]. Indeed, fibrillar Aβ deposits, the hallmark of AD and revealed by florbetapir (PiB) imaging, are more abundant and detected earlier in AD and even in cognitively normal *APO*E ε4 carriers versus noncarriers \[[@CR57], [@CR59]\]. Cognitively normal *APO*E ε4 carriers with positive amyloid imaging decline cognitively much earlier than noncarriers \[[@CR59]\]. Compared to *APO*E ε4, *APO*E ε2 appears to associate with cognitive intactness in \>90-year-old individuals even though *APO*E ε2 is also linked to higher amyloid plaque loads \[[@CR60]\]. This reported *APO*E ε2 association with amyloid plaque levels is, however, not supported by our finding that recombinant human apoE2 minimally alters Aβ~42~-α7nAChR interaction (Fig. [4](#Fig4){ref-type="fig"}).

APOE ε4 is also linked to the magnitude of neurofibrillary lesions. Although apoE is primarily produced by astrocytes and microglia in healthy states, stress or injury induce neuronal apoE expression and produce neurotoxic apoE4 fragments to increase tau hyperphosphorylation, cytoskeletal disruption, and mitochondrial dysfunction, and eventual neurodegeneration \[[@CR9], [@CR37], [@CR61], [@CR62]\]. The notion that *APO*E ε4 confers vulnerability to stress and injuries is supported by data demonstrating that neurons in *APO*E ε4 carriers with temporal lobe epilepsy are more susceptible to seizure damage and to Aβ toxicities than those harboring *APO*E ε3. \[[@CR63]\]. Despite all these linkages, the mechanism responsible for apoE4-induced tau hyperphosphorylation remains unclear. Our earlier reports showed that either incubation of synaptosomes with Aβ~42~ or intraventriculary administered Aβ~42~ induced robust tau phosphorylation at three proline-directed serine/threonine sites that are found in NFTs \[[@CR3], [@CR5], [@CR7]\]. The parallel reductions in Aβ~42~ aggregates and NFT formation by disrupting the Aβ~42~-α7nAChR interaction supports the theory that the Aβ~42~-α7nAChR association is critical to Aβ~42~-induced tau phosphorylation, and that NFTs are related to Aβ~42~ internalization, deposition, and plaque formation \[[@CR4], [@CR5], [@CR7]\]. As illustrated here, apoE4 can promote the Aβ~42~-α7nAChR interaction via apoE~141--148~ to exacerbate Aβ~42~-induced tau hyperphosphorylation that presumably leads to more extensive neurofibrillary lesions. The dose-dependency in the apoE~141--148~ enhancement of Aβ~42~-induced tau phosphorylation suggests that concentrations of apoE~141--148~ are near saturation or that the Aβ~42~ effect is near its maximum. The differential effects of astrocyte-derived versus neuron-derived apoE4 on excitotoxic damage (the former protecting against and the latter enhancing) indicate that very different apoE proteolytic pathways exist in these two cell types \[[@CR64]\].

The α7nAChRs in lymphocytes regulate the development and activation of these cells \[[@CR65]--[@CR67]\]. However, the α7nAChR expression in lymphocytes from AD subjects either increased \[[@CR68]\] or did not change \[[@CR69]\] compared to their neurologically normal peers. Similarly, we did not find *APO*E genotype- or AD-related changes in α7nAChR-like protein levels in lymphocytes (Fig. [8](#Fig8){ref-type="fig"}). These studies suggest that changes in α7nAChR and CHRFAM7A expression are likely unrelated to the increased pathogenic Aβ~42~-α7-like nAChR interaction in lymphocytes from AD subjects. The fact that markedly elevated Aβ~42~-α7nAChR complexes in the brain parallels the increased Aβ~42~-α7-like nAChR association in lymphocytes of AD patients suggests that this association in lymphocytes could potentially serve as a noninvasive, blood-based AD diagnostic biomarker \[[@CR4], [@CR7]\]. A heightened Aβ~42~-α7-like nAChR interaction in lymphocytes is also observed in this cohort of AD subjects. The magnitude of the increase in the Aβ~42~-α7-like nAChR association in lymphocytes is significantly greater in *APO*E ε4 carriers than with other *APO*E genotypes, even in AD cases. ApoE4 and perhaps neurotoxic apoE(4) fragments originating from neurons likely intensify the Aβ~42~-α7nAChR interaction to promote Aβ~42~-mediated AD pathogenesis. Aβ~42~-α7nAChR complex levels correlate with the rate of cognitive decline in the *APO*E ε4 carriers (Fig. [6c](#Fig6){ref-type="fig"}), and our current data suggest that enhancing the Aβ~42~-α7nAChR interaction may contribute to apoE4-induced AD pathologies. Hence, the Aβ~42~-α7-like nAChR complex level in lymphocytes may serve as a peripheral AD biomarker to indicate the presence of more extensive AD pathologies. Unlike the recent report using a plasma lipid profile to identify an early AD degenerative trait \[[@CR70]\], blood samples in this study were only obtained from two time points. Future experiments with different timeframes, particularly including presymptomatic time points, are needed to assess the utility of Aβ~42~-α7nAChR complex levels in lymphocytes as a biomarker for AD dementia.

In addition to α7nAChRs, expression of the α7nAChR chimeric gene, CHRFAM7A, was also found in the lymphocytes of humans \[[@CR35]\]. CHRFAM7A functions as a dominant-negative modulator of α7nAChRs in a coexpression study \[[@CR35]\] and retains the binding site for Aβ \[[@CR5], [@CR32]\], although it is unclear whether Aβ binds to CHRFAM7A with similarly high affinity as for the α7nAChRs. Our data show that the expression levels of α7nAChRs and CHRFAM7A in lymphocytes are similar in three diagnostic groups regardless of *APO*E genotype. Further, we found CHRFAM7A forms complexes with α7nAChR in vivo in the membranes of lymphocytes, although the levels of α7nAchR/CHRFAM7A complexes are comparable in different *APO*E genotypes and diagnostic groups. Importantly, the increased Aβ~42~ association with α7nAChRs and/or CHRFAM7As in lymphocytes from AD subjects agrees with previous findings in postmortem human brains and in human lymphocytes \[[@CR4], [@CR7], [@CR32]\].

The immune system interacts with the brain bidirectionally through common receptors and ligands, such as interleukin-1β and other proinflammatory cytokines \[[@CR71], [@CR72]\]. We showed that the induction of plasticity-related phenomena in the brain similarly affects lymphocyte function \[[@CR73]\]. Moreover, lymphocytes from senescent mice transferred to young mice decreased the learning abilities of these mice to the level of senescent mice and produced senescence-like serum-brain reactivity \[[@CR74]\]. As in postmortem brains, lymphocytes derived from AD patients and ex vivo incubation of lymphocytes from normal controls with Aβ~42~ showed substantially higher α7nAChR-TLR4-filamin A complexes \[[@CR7]\]. Our finding that Aβ~42~-α7-like nAChR complexes in lymphocytes correlate with effects on the synaptic Aβ~42~-α7nAChR interaction by plasma from *APO*E ε4 carriers and AD patients suggests similar apoE4 influences in the brain and the periphery. We therefore believe that the Aβ~42~-α7-like nAChR complex level in lymphocytes may be used as an antecedent biomarker to gauge AD neuropathogenic progression during the prodromal phase of the disease given that pathological changes occur considerably earlier than cognitive impairments. This novel potential biomarker holds a higher pathogenic rationale than many other blood-based biomarkers such as lipid profiling \[[@CR70]\] and autoantibody panels \[[@CR75]\]. Neuroinflammation is intimately involved in AD, and certain systemic leukocytes are relatively long lived; it is then possible these immune cells detect neuronal pathological changes and respond by altering molecules within themselves such as T-cell activation markers or their phenotypes \[[@CR76]\]. Together with our current finding of AD-related changes in lymphocytes, these data suggest that, during AD progression, brain pathologies may lead to systematic and long-term immunological changes in lymphocytes and other blood cells. Changes induced by apoE4 in peripheral immune cells such as increased Aβ~42~-α7nAChR interaction may be potential AD biomarkers.

Finally, apoE is required for deposition of Aβ fibrils in amyloid mouse models \[[@CR52]\]. Genetic knockdown of human apoE reduces amyloid plaque loads in transgenic AD mouse models, regardless of apoE isoform \[[@CR77]\]. Interestingly, Aβ~12--28~, which prevents the Aβ~42~-α7nAChR interaction \[[@CR4], [@CR32]\], also blocks apoE-driven Aβ deposition and ameliorates memory deficits in AD transgenic mouse models with elevated amyloid \[[@CR78]\]. Agents that reduce Aβ~42~-α7nAChR complex levels decrease Aβ~42~ aggregates, hyperphosphorylated tau (NFTs), and synaptic pathology in AD mouse models \[[@CR5]--[@CR7], [@CR79]\]. Because apoE(4) promotes the Aβ~42~-α7nAChR interaction, blocking this interaction may prevent apoE4 and its toxic fragments from promoting Aβ-mediated, α7nAChR-dependent AD pathogenesis in *APO*E ε4 carriers.

A few limitations warrant caution in drawing conclusions from this study. First, because clinical diagnosis is based mainly on cognitive symptoms, the precise brain AD pathologies are not known. Second, despite well-matched pairs, the number of cases in this study is small, especially in the APOE ε2/ε3 cohort. Third, the apoE peptides were used primarily to illustrate the phenomenon rather than to provide quantitative measurements. Last, although the increased Aβ~42~-α7nAChR complex levels correlate with progression of cognitive decline in AD, whether the Aβ~42~-α7nAChR association enhancement by apoE accelerates AD pathology is ambiguous. Further research is needed to fully elucidate the contribution of the apoE4-induced increase in the Aβ~42~-α7nAChR interaction to AD pathogenesis.

Conclusion {#Sec24}
==========

Our data obtained from well-matched pairs in the ROSAS cohorts suggests that increased lymphocyte Aβ~42~-α7nAChR-like complexes may be a potential biomarker for AD pathologies. Importantly, we show that apoE4 enhances the Aβ~42~-α7nAChR interaction through apoE~141--148~ to contribute to apoE4-driven, Aβ~42~-mediated neurodysfunction and pathologies. Therapeutic agents that prevent or disrupt the Aβ~42~-α7nAChR association should be considered as disease-modifying therapeutics for AD patients, including *APO*E ε4 carriers.
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